Introduction

Managing Group 2 Pulmonary Hypertension remains a significant challenge for clinicians globally. A recent Japanese multicenter registry study published in the Journal of the American Heart Association (JAHA) has shed new light on this condition. The study investigates how pulmonary vascular resistance (PVR) affects long-term prognosis. Interestingly, researchers also explored the impact of modern heart failure therapies like SGLT2 inhibitors on these high-risk patients.

Prognostic Significance of PVR in Group 2 Pulmonary Hypertension

Group 2 Pulmonary Hypertension typically results from left heart disease, such as valvular issues or heart failure. In this registry, clinicians analyzed two distinct cohorts spanning over a decade. They found that elevated PVR acts as a primary driver of adverse outcomes. Specifically, patients with a PVR of 3 Wood units or higher faced a significantly higher risk of hospitalization or death. This prognostic link remained consistent across different types of heart failure. Both patients with reduced and preserved ejection fractions showed similar patterns. Consequently, measuring PVR accurately through right heart catheterization is vital for risk stratification.

Role of SGLT2 Inhibitors in Management

The most promising finding involves the use of SGLT2 inhibitors. In the current registry, patients treated with these agents showed markedly better event-free rates. Specifically, those on SGLT2 inhibitors had a 73.8% event-free rate. In contrast, those without treatment had an event-free rate of only 35.5%. Therefore, these medications might offer a new therapeutic avenue for managing pulmonary hemodynamics. While these results are encouraging, they are based on observational registry data. Thus, we need further controlled clinical trials to confirm the efficacy of SGLT2 inhibitors in this specific population. However, the study provides a strong rationale for using these drugs in patients with elevated PVR.

FAQs

What is Group 2 Pulmonary Hypertension?

Group 2 PH is a condition where high blood pressure in the lung arteries occurs due to left-sided heart diseases, such as heart failure or mitral valve disease.

Why is PVR 3 Wood units a significant threshold?

A PVR of 3 Wood units serves as a critical clinical marker. It helps identify patients at a significantly higher risk for mortality and heart failure-related hospitalizations.

Can SGLT2 inhibitors be used for Group 2 PH?

Evidence suggests SGLT2 inhibitors may improve outcomes in Group 2 PH patients with elevated PVR, although further randomized controlled trials are needed for a definitive recommendation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Satoh T et al. Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. J Am Heart Assoc. 2026 Mar 20. doi: 10.1161/JAHA.125.045155. PMID: 41859897.
2. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731.
3. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117-2128.